Nivolumab May Be Safe, Effective for Platinum-Resistant Ovarian Cancer

Share this content:
Nivolumab has demonstrated encouraging safety and clinical efficacy data in patients with platinum-resistant ovarian cancer.
Nivolumab has demonstrated encouraging safety and clinical efficacy data in patients with platinum-resistant ovarian cancer.

Nivolumab has demonstrated encouraging safety and clinical efficacy data in patients with platinum-resistant ovarian cancer, a new study published online ahead of print in the Journal of Clinical Oncology.1

For the phase 2 study, researchers enrolled 20 women with platinum-resistant ovarian cancer and assigned them to receive nivolumab 1 or 3 mg/kg intravenously every 2 weeks.

Results showed that the best overall response was 15% with two patients achieving a durable complete response, which occurred in the 3 mg/kg cohort. Median progression-free survival was 3.5 months (95% CI: 1.7, 3.9) and the median overall survival was 20.0 months (95% CI: 7.0, not reached) at the time of study termination.

In regard to safety, 40% of the 20 patients experienced grade 3 or 4 treatment-related adverse events. Two patients experienced severe adverse events.

RELATED: Nonselective Beta-Blocker Use May Raise Survival in Ovarian Cancers

The findings indicate that large-scale investigations should be conducted to further evaluate the efficacy and safety of nivolumab in patients with platinum-resistant ovarian cancer.

Nivolumab is already approved by the U.S. Food and Drug Administration (FDA) for the treatment of unresectable or metastatic melanoma and metastatic squamous non-small cell lung cancer.

Reference

  1. Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer [published online ahead of print September 8, 2015]. J Clin Oncol. doi: 10.1200/JCO.2015.62.3397.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters